Recruiting NCT05089747
CIRculating CANcer MAster-Protocol
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Blood sampling for biomarker analysis (microRNA, circulating DNA…).
- Who it may be relevant to
- Registry conditions: Adult With Solid Cancer. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
MAster Protocol Studying the Impact of Blood Biopsy on Screening, Diagnosis, Diagnostic and Follow-up of Solid Cancer in Adult
Overview
This exploratory study will focus on the development of the analyses of blood biomarkers to better understand the circulating biomarkers associated with cancer diagnosis, treatment efficacy and progressive disease
Interventions
- Biological Blood sampling for biomarker analysis (microRNA, circulating DNA…)
From one to four blood samplings: at diagnosis, after the first cycle of treatment, end of treatment, progressive disease (or end of study).
Primary outcome measures
- Liquid biopsy analyses [Time frame: Day 0]
- Standard technics of disease assessment [Time frame: Week 16]
- Correlation between outcome 1 and outcome 2 [Time frame: year 5]
Eligibility criteria
Inclusion criteria
- Adult (>18y)
- Owing a social security insurance
- Any solid cancer diagnosed by histopathology or cytology
- Patient with blood sampling required as per standard of care
- Informed consent signed
Exclusion criteria
- Refusal to participate
- No blood sampling required as per standard of care
- Hemoglobin < 7g/dl (< 9g/dl if respiratory or cardiovascular disease history)
- Heterologous blood transfusion in the last 48 hours
- Weight under 20 kg
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
France · 7 centers
- Service de Pneumologie Hôpital Louis Pradel / Groupement Hospitalier Est — Bron
- Hôpital Edouard Herriot / Groupement Hospitalier Centre — Lyon
- Service de Pneumologie Hôpital Croix-Rousse / Groupement Hospitalier Nord — Lyon
- Service de Pneumologie Aigue Spécialisée et Cancérologie Thoracique Hôpital Lyon-Sud / Gro — Pierre-Bénite
- Hôpital Lyon-Sud / Groupement Hospitalier Sud — Pierre-Bénite
- Oncologie médicale Hôpital Lyon-Sud / Groupement Hospitalier Sud — Pierre-Bénite
- Service de dermatologie Hôpital Lyon-Sud / Groupement Hospitalier Sud — Pierre-Bénite
Identifiers
NCT: NCT05089747 · 69HCL21_0918